Close Menu

NEW YORK– Myriad Genetics reported after the close of the market on Thursday that its fiscal second quarter revenues declined 10 percent year over year due to billing issues in its prenatal business.

For the three months ended Dec. 31, 2019 the firm reported total revenues of $195.1 million, compared to $216.8 million in the year-ago period and far short of the consensus Wall Street estimate of $209.8 million, and its previously stated guidance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.